BR112015007095A8 - derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados - Google Patents

derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados Download PDF

Info

Publication number: BR112015007095A8
Authority: BR; Brazil
Prior art keywords: derivatives; dihydro; azafenalene; snc; treatment
Prior art date: 2012-09-28

Application number

BR112015007095A

Other languages

English (en)

Portuguese (pt)

Other versions

BR112015007095A2 (pt

Inventor

Rosenfeld Craig

Nguyen Dieu

j norman James

R Loebelenz Jean

A Gladding Jeffery

C Warner John

W Lee John

Thota Sambaiah

R Cheruku Srinivasa

Original Assignee

Warner Babcock Inst For Green Chemistry Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-28

Filing date

2013-09-27

Publication date

2019-08-20

2013-09-27 Application filed by Warner Babcock Inst For Green Chemistry Llc filed Critical Warner Babcock Inst For Green Chemistry Llc

2017-07-04 Publication of BR112015007095A2 publication Critical patent/BR112015007095A2/pt

2019-08-20 Publication of BR112015007095A8 publication Critical patent/BR112015007095A8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Epidemiology (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BR112015007095A 2012-09-28 2013-09-27 derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados BR112015007095A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261707444P	2012-09-28	2012-09-28
PCT/US2013/062429 WO2014052906A1 (fr)	2012-09-28	2013-09-27	Dérivés de dihydro-6-azaphénalène pour le traitement du snc, de maladies oncologiques et de troubles apparentés

Publications (2)

Publication Number	Publication Date
BR112015007095A2 BR112015007095A2 (pt)	2017-07-04
BR112015007095A8 true BR112015007095A8 (pt)	2019-08-20

Family

ID=50385790

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112015007095A BR112015007095A8 (pt)	2012-09-28	2013-09-27	derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados

Country Status (10)

Country	Link
US (1)	US10047089B2 (fr)
EP (1)	EP2900239B1 (fr)
JP (1)	JP6345674B2 (fr)
KR (1)	KR20150060775A (fr)
CN (1)	CN104994853B (fr)
AU (1)	AU2013323198B2 (fr)
BR (1)	BR112015007095A8 (fr)
CA (1)	CA2886749A1 (fr)
IL (1)	IL237912B (fr)
WO (1)	WO2014052906A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106316966A (zh) *	2015-06-15	2017-01-11	董运勤	医药中间体n-(2-吡嗪甲基)苄胺磷酸盐化合物制备方法
CN108699019B (zh) *	2015-11-11	2022-05-10	华纳巴布科克绿色化学学院有限公司	用于治疗中枢神经系统和其他疾病的苯并呋喃衍生物
WO2018208709A1 (fr)	2017-05-09	2018-11-15	Warner Babcock Institute For Green Chemistry, Llc	Dérivés de stilbène à utiliser pour le traitement de troubles du snc et d'autres troubles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3614414A1 (de)	1986-04-29	1987-11-05	Knoll Ag	Neue benzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
JPH03232858A (ja)	1990-02-07	1991-10-16	Toyo Pharma- Kk	１，８―ナフタル酸イミド誘導体とその製法及び用途
US6417178B1 (en)	1994-07-19	2002-07-09	University Of Pittsburgh	Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
JP2002515490A (ja)	1998-05-15	2002-05-28	ギルフォードファーマシューティカルズインコーポレイテッド	Ｐａｒｐ活性を抑制する縮合三環化合物
US6380193B1 (en)	1998-05-15	2002-04-30	Guilford Pharmaceuticals Inc.	Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US20040106548A1 (en) *	2001-09-07	2004-06-03	Schmidt Michelle A	Conformationally constrained labeled peptides for imaging and therapy
AU2002950217A0 (en)	2002-07-16	2002-09-12	Prana Biotechnology Limited	8- Hydroxy Quinoline Derivatives
EP1633362B1 (fr) *	2003-05-28	2012-09-26	Eisai Inc.	Composes, procedes et compositions pharmaceutiques destines a l'inhibition de la parp
WO2007030939A2 (fr)	2005-09-15	2007-03-22	Painceptor Pharma Corporation	Methodes de modulation de l'activite induite par la neurotrophine
FR2927077B1 (fr)	2008-01-31	2012-05-25	Commissariat Energie Atomique	Derives du 1,8-naphtalimide en tant qu'agents de scintillation notamment pour la discrimination entre les neutrons rapides et les rayons gamma
CN102603695B (zh)	2012-02-10	2014-06-18	山东大学	一种氨基酸-荧光团类化合物及其应用

2013
- 2013-09-27 CN CN201380062135.4A patent/CN104994853B/zh not_active Expired - Fee Related
- 2013-09-27 KR KR1020157009764A patent/KR20150060775A/ko not_active Application Discontinuation
- 2013-09-27 WO PCT/US2013/062429 patent/WO2014052906A1/fr active Application Filing
- 2013-09-27 US US14/040,393 patent/US10047089B2/en active Active
- 2013-09-27 JP JP2015534773A patent/JP6345674B2/ja not_active Expired - Fee Related
- 2013-09-27 AU AU2013323198A patent/AU2013323198B2/en not_active Ceased
- 2013-09-27 BR BR112015007095A patent/BR112015007095A8/pt not_active Application Discontinuation
- 2013-09-27 EP EP13842204.3A patent/EP2900239B1/fr not_active Not-in-force
- 2013-09-27 CA CA 2886749 patent/CA2886749A1/fr not_active Abandoned
2015
- 2015-03-23 IL IL237912A patent/IL237912B/en active IP Right Grant

Also Published As

Publication number	Publication date
EP2900239A1 (fr)	2015-08-05
EP2900239A4 (fr)	2016-04-20
US10047089B2 (en)	2018-08-14
CA2886749A1 (fr)	2014-04-03
JP6345674B2 (ja)	2018-06-20
JP2015531379A (ja)	2015-11-02
IL237912B (en)	2019-08-29
CN104994853B (zh)	2018-11-30
BR112015007095A2 (pt)	2017-07-04
WO2014052906A1 (fr)	2014-04-03
CN104994853A (zh)	2015-10-21
KR20150060775A (ko)	2015-06-03
AU2013323198A1 (en)	2015-04-09
EP2900239B1 (fr)	2019-03-20
IL237912A0 (en)	2015-05-31
AU2013323198B2 (en)	2018-03-29
US20140094487A1 (en)	2014-04-03

Publication	Publication Date	Title
BR112015022197A8 (pt)	2019-11-26	uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015003188A2 (pt)	2017-08-22	Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015008447A2 (pt)	2017-07-04	métodos para tratar câncer
BR112014008789A2 (pt)	2017-04-25	prevenção e tratamento de condições oculares
BR112014026703A2 (pt)	2017-06-27	inibidores de dna-pk
BR112015003590A8 (pt)	2017-10-31	Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
BR112015001847A2 (pt)	2017-07-04	composições e tratamento para doenças e distúrbios nos olhos
BR112014032699A2 (pt)	2017-06-27	métodos de tratamento de síndrome metabólica pediátrica
BR112013029537A2 (pt)	2017-01-24	derivados de quinazolina para tratamento de infecções virais e outras doenças
BR112015010477A2 (pt)	2017-07-11	combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
BR112015028879A8 (pt)	2019-12-31	compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015007778A2 (pt)	2017-07-04	profármacos neutralizantes de vegf para o tratamento de condições oculares
EA201590654A1 (ru)	2015-12-30	Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201590655A1 (ru)	2015-12-30	Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112015022514A2 (pt)	2017-07-18	composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112013031652A2 (pt)	2019-09-24	métodos de tratamento para doenças retinais
CL2015000039A1 (es)	2015-03-27	Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112016027043A8 (pt)	2021-07-20	combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
AR091724A1 (es)	2015-02-25	Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
BR112015028516A2 (pt)	2017-07-25	tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112017021583A2 (pt)	2018-07-03	métodos para o tratamento de transtornos inflamatórios
BR102012028120B8 (pt)	2022-08-02	Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
BR112014015578A2 (pt)	2017-06-13	composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112015007095A8 (pt)	2019-08-20	derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
BR112016016098A2 (pt)	2017-08-08	Compostos orgânicos

Legal Events

Date	Code	Title	Description
2018-03-06	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-03-06	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-13	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-03-20	B06I	Publication of requirement cancelled [chapter 6.9 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.
2019-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-01-07	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-06-30	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements